Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Johnson & Johnson (JNJ) Stock Moves -0.03%: What You Should Know
by Zacks Equity Research
The latest trading day saw Johnson & Johnson (JNJ) settling at $157.73, representing a -0.03% change from its previous close.
AI ETFs: Q1 of 2024 Update
by Sanghamitra Saha
The year 2023 was crucial in the Artificial Intelligence (AI) industry. So far this year, we have seen Apple's efforts to join the AI race more prudently, Amazon's billion dollar investment in AI start-up and Nvidia's efforts to foray into various industries with AI initiatives.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Shockwave Medical (SWAV) Up on Potential Acquisition Rumors
by Zacks Equity Research
Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
by Kinjel Shah
While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
4 Best ETF Areas of Q1
by Sanghamitra Saha
Wall Street is poised to conclude the first quarter with robust gains due to a likely dovish Fed and robust economic as well as earnings growth.
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
by Zacks Equity Research
Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.
Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $155.77, marking a +0.35% move from the previous day.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
by Zacks Equity Research
Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.
GE HealthCare (GEHC) Uses AI Solution to Boost Medical Imaging
by Zacks Equity Research
GE HealthCare's (GEHC) SonoSAMTrack demonstrates its pliability and applicability in ultrasound image segmentation by using NVIDIA's technology.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
by Kinjel Shah
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%
by Zacks Equity Research
Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.
Johnson & Johnson (JNJ), Nvidia Unite to Boost AI for Surgery
by Zacks Equity Research
Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $156.76, moving -0.9% from the previous trading session.
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
by Zacks Equity Research
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
J&J (JNJ) Gets FDA Panel Vote for Carvykti's Expanded Use
by Zacks Equity Research
J&J (JNJ) is looking for expansion of Carvykti's label for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma.
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
by Kinjel Shah
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The Zacks Analyst Blog Highlights UnitedHealth Johnson & Johnson, Oracle, Wells Fargo & Co and Caterpillar.
by Zacks Equity Research
UnitedHealth, Johnson & Johnson, Oracle, Wells Fargo & Co and Caterpillar are the part of the Zacks top Analyst Blog .
Top Stock Reports for UnitedHealth, Johnson & Johnson & Oracle
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ) and Oracle Corporation (ORCL).
J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis
by Zacks Equity Research
Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.